Citation Tools

Download PDFPDF
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

Download to a citation manager

Cite this article as:
Piccart MJ, Bertelsen K, Stuart G, et al
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer